About Lyka Labs Ltd 
Lyka Labs Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company.
Company Coordinates 
Company Details
4801/B & 4802/A, GIDC Industrial Estate Ankleshwar Gujarat : 393002
Registrar Details
Sharex Dynamic (India) Pvt Ltd , Unit -1, Luthra Ind. Premises , Safed Pool, Andheri-Kurla Road, Andheri (E), Mumbai
Capital Structure 
Present Equity Capital
INR 35.69 Cr
Number of Shares
3.57 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
16-Apr-2024
3.57
35.69
2600000
10
Conversion of Warrants
18-Apr-2023
3.31
33.09
2400000
10
Conversion of Warrants
15-Mar-2023
3.07
30.69
2000000
10
Preferential Issue Of Shares
09-Aug-2019
2.87
28.69
550000
10
Conversion of Warrants
16-Aug-2017
2.81
28.14
6100000
10
Allotment of Equity To Others
16-Aug-2017
2.81
28.14
6100000
10
Allotment of Equity To Others
02-Nov-2015
2.2
22.04
460000
10
Allotment of Equity Shares To Promoter & Others
02-Nov-2015
2.2
22.04
460000
10
Allotment of Equity Shares To Promoter & Others
11-Jun-2008
2.16
21.58
650000
10
Conversion of Warrants
11-Jun-2008
2.16
21.58
650000
10
Conversion of Warrants
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 4 Schemes (0.01%)
FIIs
Held by 5 FIIs (0.18%)
Promoter with highest holding
Ipca Laboratories Limited (40.98%)
Highest Public shareholder
Thermo Capital Private Limited (1.68%)
Individual Investors Holdings
31.52%
Management
Designation
Remuneration
KUNAL NARENDRA GANDHI
Chairman & MD & CEO
1.52 cr
Sandeep P Parikh
Non-Exec. & Independent Dir.
3.2 lacs
Yogesh B Shah
Executive Director & CFO
20.8 lacs
Dhara P. Shah
Non-Exec. & Independent Dir.
2.7 lacs
Kishore P Shah
Company Sec. & Compli. Officer
0
Babulal Jain
Independent Director
2.1 lacs
Prashant Godha
Director
1.8 lacs
Shashil Mendonsa
Director
1.5 lacs
Raw Materials Dashboard 
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Dashboard 
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Royalty
0.32
0.77%
Royalty
Royalty
Revenue and Profits:
Net Sales:
37 Cr
(Quarterly Results - Sep 2025)
Net Profit:
-3 Cr
Pharmaceuticals & Biotechnology
INR 283 Cr (Micro Cap)
141.00
34
0.00%
0.30
2.02%
2.84






